Arcadia Biosciences, Inc.
RKDA
$3.60
$0.020.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.29% | 11.41% | 21.58% | 56.50% | 18.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.29% | 11.41% | 21.58% | 56.50% | 18.41% |
| Cost of Revenue | -16.29% | 29.55% | 42.98% | 2,680.00% | 27.23% |
| Gross Profit | -13.10% | -6.18% | 1.57% | -30.72% | 2.78% |
| SG&A Expenses | -29.94% | -20.87% | -15.71% | 56.60% | 20.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.57% | -11.12% | -4.69% | 94.58% | 22.34% |
| Operating Income | 34.55% | 25.69% | 21.39% | -126.06% | -25.98% |
| Income Before Tax | 172.42% | -340.97% | 374.45% | -805.39% | -84.98% |
| Income Tax Expenses | -- | -- | -- | 14.29% | -- |
| Earnings from Continuing Operations | 172.42% | -340.97% | 374.45% | -793.14% | -84.98% |
| Earnings from Discontinued Operations | -- | -- | -- | 98.88% | 77.70% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 153.10% | -520.17% | 207.26% | -42.45% | 37.20% |
| EBIT | 34.55% | 25.69% | 21.39% | -126.06% | -25.98% |
| EBITDA | 34.40% | 25.18% | 19.59% | -139.09% | -34.02% |
| EPS Basic | 152.97% | -518.90% | 206.92% | -42.11% | 37.40% |
| Normalized Basic EPS | 172.24% | -153.08% | 192.90% | -1,913.96% | -84.38% |
| EPS Diluted | 152.31% | -1,076.96% | 206.50% | -42.11% | 37.23% |
| Normalized Diluted EPS | 172.00% | -210.26% | 192.90% | -1,913.96% | -84.38% |
| Average Basic Shares Outstanding | 0.25% | 0.31% | 0.32% | 0.24% | 0.32% |
| Average Diluted Shares Outstanding | 0.59% | -18.18% | 0.33% | 0.24% | 0.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |